Rheumatoid Arthritis
Conference Coverage
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
From the Journals
Investigational drug peresolimab shows efficacy in patients with RA
Only patients taking peresolimab 700 mg had a significantly greater change in Disease Activity Score in 28 Joints based on the C-reactive protein...
From the Journals
Rheumatoid arthritis linked to increased Parkinson’s risk
“If patients with rheumatoid arthritis begin exhibiting motor symptoms such as muscle rigidity, tremors, or slowed movement, it is imperative that...
Conference Coverage
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
In about 5% of patients with seropositive RA, C-reactive protein levels were normal despite disease flares during a 5-year period. The findings...
Latest News
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
The announcement came after a pulmonary embolism occurred with the 12-mg twice-daily dose in one of the long-term open-label extension studies.
Feature
Researchers seek to understand post-COVID autoimmune disease risk
Three large studies link past SARS-CoV-2 infection to new-onset autoimmune disease, but it is not yet clear what drives this relationship.
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Conference Coverage
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs. anti–tumor necrosis factor (TNF) therapy for rheumatoid...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...